Other Information
−Removed: During the three months ended December 28, 2024, none of our directors or officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock.
+Added: During the three months ended June 28, 2025, none of our directors or officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock.
+Added: Exhibit Number Description
Restated Articles of Organization of the Company, reflecting Articles of Amendment dated August 23, 1993, August 21, 2006, July 26, 2018 and July 25, 2019 (filed as Exhibit 3.1 to the Company’s Form 8-K dated July 29, 2019 and incorporated herein by reference).
By-Laws of the Company, as amended through June 29, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K dated June 30, 2020 and incorporated herein by reference).
+Added: Form of Performance Share Unit Award Agreement under 2019 Long-Term Incentive Compensation Plan (AAGR) (adopted fiscal 2026) (1).
Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Christopher A.
6 unchanged sentences
D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
−Removed: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended December 28, 2024 formatted in inline Extensible Business Reporting Language (XBRL) includes:
−Removed: (i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statement of Stockholders' Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
+Added: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended June 28, 2025 formatted in inline Extensible Business Reporting Language (XBRL) includes:
+Added: (i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statement of Stockholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Condensed Consolidated Financial Statements.
104* Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
1 unchanged sentence
** Document furnished with this report.
+Added: (1) Agreement, plan, or arrangement related to the compensation of officers or directors.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HAEMONETICS CORPORATION
−Removed: February 6, 2025 By:
+Added: August 7, 2025 By:
/s/ Christopher A.
2 unchanged sentences
(Principal Executive Officer)
−Removed: February 6, 2025 By:
+Added: August 7, 2025 By:
D’Arecca, Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.